Last reviewed · How we verify
Spravato
Spravato, developed by Yale University, is a marketed treatment for depressive disorder. Its key composition patent is set to expire in 2028, providing a period of exclusivity that supports its market position. The primary risk lies in the lack of reported revenue and key trial results, which may affect investor confidence and market adoption.
At a glance
| Generic name | Spravato |
|---|---|
| Sponsor | Yale University |
| Target | Glutamate NMDA receptor |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
| Annual revenue | 800 |
Approved indications
- Depressive disorder
Common side effects
- Dissociation
- Dizziness
- Nausea
- Sedation
- Vertigo
- Hypoesthesia
- Anxiety
- Lethargy
- Blood Pressure Increased
- Vomiting
- Feeling Drunk
- Headache
Serious adverse events
- Suicidal Ideation
- Blood Pressure Increased
- Dizziness
- Dissociation
- Nausea
- Vomiting
- Headache
- Muscular Weakness
- Vertigo
- Hypertension
Key clinical trials
- Correlating EEG Dynamics With Consciousness Alteration Under Anesthesia
- A Study of CLE-100 (Oral Esketamine) as an Adjunctive Treatment to Standard Antidepressants for Major Depressive Disorder (PHASE2)
- Phenomenological Explorations of the Esketamine-Induced Transient Dissociative State (NA)
- Intranasal Dexmedetomidine-esketamine Administration and Postoperative Pain in Pediatric Patients (PHASE4)
- Effect of Esketamine on Postoperative Sleep in Postmenopausal Women (NA)
- A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder (PHASE3)
- A Study of Esketamine Nasal Spray in Korean Participants With Treatment-resistant Depression (PHASE4)
- KF2024#1-trial: Esketamine Interaction Study (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| SEC EDGAR | Revenue + earnings |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Spravato CI brief — competitive landscape report
- Spravato updates RSS · CI watch RSS
- Yale University portfolio CI